Details

CAR T therapy in adult DLBCL patients in Slovenia : evaluation of predictive scores for outcomes and adverse events
ID Sršen, Lucija (Author), ID Auersperger, Irena (Author), ID Janžič, Larisa (Author), ID Kopitar, Andreja Nataša (Author), ID Reberšek, Katarina (Author), ID Jezeršek Novaković, Barbara (Author), ID Novak, Polona (Author), ID Rener, Karla (Author), ID Šlajpah, Klara (Author), ID Ihan, Alojz (Author), ID Zver, Samo (Author), ID Sever, Matjaž (Author)

.pdfPDF - Presentation file, Download (5,91 MB)
MD5: 53B82CDDF44A9AD52C8A607F1AEC051E
URLURL - Source URL, Visit https://www.tandfonline.com/doi/full/10.1080/21645515.2026.2620889 This link opens in a new window

Abstract
CAR T cell therapy is a promising immunotherapy for hematologic malignancies, yet early prediction of outcomes and adverse events remains difficult, especially in small real-world cohorts. We retrospectively analyzed 14 adult patients with diffuse large B-cell lymphoma (DLBCL) treated with CAR T cells in Slovenia, assessing IL-6 increase rates and established predictive metrics including EASIX-C, CAR-HEMATOTOX, and IBPS on Day −5 (pre-lymphodepletion) and Day 0 (infusion). Contrary to our expectation, an inverse correlation was observed between the increase rate of IL-6 and the occurrence of severe cytopenias, indicating higher IL-6 increase rate leads to less severe cytopenias. The EASIX-C score showed higher predictive values when calculated on Day 0, contrary to the CAR-HEMATOTOX score, whose higher predictive values were observed on Day −5. The IBPS predictive values showed mixed results when comparing Day −5 to Day 0. We observed 50% response rate and 29% remission rate. The results highlight the utility of predictive scores, with unexpected findings on IL-6 suggesting further study is necessary.

Language:English
Keywords:CAR T cell therapy, hematologic malignancies, diffuse large B-cell lymphoma, predictive scores, adverse events, therapeutic outcomes
Work type:Article
Typology:1.01 - Original Scientific Article
Organization:MF - Faculty of Medicine
Publication status:Published
Publication version:Version of Record
Year:2026
Number of pages:12 str.
Numbering:Vol. 22, no. 1, art. 2620889
PID:20.500.12556/RUL-181494 This link opens in a new window
UDC:616.1
ISSN on article:2164-5515
DOI:10.1080/21645515.2026.2620889 This link opens in a new window
COBISS.SI-ID:267251459 This link opens in a new window
Publication date in RUL:09.04.2026
Views:332
Downloads:225
Metadata:XML DC-XML DC-RDF
:
Copy citation
Share:Bookmark and Share

Record is a part of a journal

Title:Human vaccines & immunotherapeutics
Shortened title:Hum. vaccin. immunother.
Publisher:Taylor & Francis
ISSN:2164-5515
COBISS.SI-ID:4534392 This link opens in a new window

Licences

License:CC BY-NC 4.0, Creative Commons Attribution-NonCommercial 4.0 International
Link:http://creativecommons.org/licenses/by-nc/4.0/
Description:A creative commons license that bans commercial use, but the users don’t have to license their derivative works on the same terms.

Secondary language

Language:Slovenian
Keywords:celično zdravljenje CAR T, hematološke maligne bolezni, difuzni velikocelični limfom, neželeni učinki

Projects

Funder:ARIS - Slovenian Research and Innovation Agency
Funding programme:Young researchers

Funder:ARIS - Slovenian Research and Innovation Agency
Project number:P3-0083
Name:Odnosi parazitskega obstajanja

Funder:ARIS - Slovenian Research and Innovation Agency
Project number:P3-0289
Name:Značilnosti malignih neoplazem, pomembne za diagnozo ter napoved poteka bolezni in izida zdravljenja

Similar documents

Similar works from RUL:
Similar works from other Slovenian collections:

Back